Abstract: Catalytic dehydration-hydrolysis process for the co-production of acetic acid and dimethyl ether from a mixture of methanol and methyl acetate and water in which the amount of water fed to the process is controlled by the steps of dehydrating a methanol feed to provide a crude product containing dimethyl ether, unconverted methanol and water, recovering therefrom a stream containing dimethyl ether, water and methanol and a water stream and separating dimethyl ether from the dimethyl-ether containing stream to produce a methanol stream containing methanol and water. At least part of the methanol stream and methyl acetate is supplied to the dehydration-hydrolysis process.

Abstract: Method for extracting ferulic acid and/or its salts from a previously conditioned source rich in ferulic acid and its salts which comprises adsorbing the ferulic acid and/or its salts on a column packed with synthetic resin, desorbing the ferulic acid and/or its salts using an organic solvent, separating the liquor rich in ferulic acid into two fractions according to their water content, separately concentrating the two liquor fractions, mixing and concentrating said fractions, adding 2 volumes of water to them, concentrating the mixture obtained, separating out the insoluble impurities by sedimentation, pre-crystallizing the ferulic acid and/or its salts with a synthetic purification resin, crystallizing out the ferulic acid and/or its salts, separating the ferulic acid and/or its salts from the crystallization mother liquors and drying it and screening it.

Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.

Abstract: Homochiral metal organic framework (MOF) selected from a group consisting of (Sp)-P5A-MOF-1 and (Rp)-P5A-MOF-1 is provided. The homochiral MOFs are prepared from pure enantiomer struts of formula (I): The homochiral MOFs are suitable for separation of enantiomers from racemic mixtures.

Abstract: Cis and trans ruthenium complexes that can be used as catalysts for ring opening metathesis polymerization (ROMP) are described. The complexes are generally square pyramidal in nature, having two anionic ligands X. Corresponding cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand are also described. Polymers such as polydicyclopentadiene (PDCPD) can be prepared using the catalysts.

Abstract: The invention relates to a process for doubly carbonylating allyl ethers to the corresponding diesters, wherein a linear or branched allyl ether is reacted with a linear or branched alkanol (alcohol) with supply of CO and in the presence of a catalytic system composed of a palladium complex and at least one organic phosphorus ligand and in the presence of a hydrogen halide selected from HCl, HBr and HI.

Abstract: Provided are compounds of the following: wherein R1 is a saturated or unsaturated cyclic hydrocarbon optionally substituted with an alkyl and/or an OXO-ester, and R2 is a C4 to C14 hydrocarbyl, preferably the residue of a C4 to C14 OXO-alcohol. Also provided are processes for making the compounds and plasticized polymer compositions containing said compounds.

Abstract: Position-1 halogen can be selectively reduced by reacting a compound represented by formula (3): [wherein X represents a chlorine atom, a bromine atom, or an iodine atom] with halogen in the presence of a heterogeneous transition metal catalyst to produce 2-(halogenomethyl)-1-methyl-3-nitrobenzene represented by formula (1): [wherein the symbol is as defined above].

Abstract: The present invention provides a process for preparing di- and polyamines from the diphenylmethane series by converting aniline and formaldehyde in the absence of an acid catalyst to give aminal and water, removing the aqueous phase and further processing the organic aminal phase to give the di- and polyamines of the diphenylmethane series, in which use of a coalescence aid in the phase separation of the process product obtained in aminal reaction reduces the proportion of water and hence also of water-soluble impurities in the organic phase containing the aminal. The di- and polyamines of the diphenylmethane series obtained by acid-catalyzed rearrangement and workup after further processing of the aminal phase are outstanding suitably for preparation of the corresponding isocyanates.

Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.

Abstract: The present invention refers to a method for the synthesis of a compound of formula (I), solvates, stereoisomers or salts thereof, a key intermediate in the synthesis of Mirabegron by reduction of an amide in the presence of an amine-boranecomplex, wherein the amine is an aniline.

Abstract: The present disclosure relates to processes for the preparation of 2-amino-1,3-propane diol compounds and their hydrochloride salts. Particularly, the present disclosure relates to processes for synthesizing 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol and its hydrochloride salt 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride respectively. The said process is safe, commercially feasible for large-scale synthesis and has improved efficacy along with many other advantages. The present disclosure also relates to the novel polymorphs of 2-amino-1,3-propane diol compound and its hydrochloride salt, where in 2-amino-1,3-propane diol compound is 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol, and its hydrochloride salt is 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride.

Abstract: The invention relates to glutamic acid N,N-diacetic acid (GLDA) of the formula GLDA-YmHn, wherein m is less than 0.5, n+m=4, Y is a monovalent cation that is not a proton, in the form of crystals, a process to make these crystals, and their uses, in particular in detergent compositions.

Abstract: A new azobenzene-based fluorescence quencher with excellent solubility in aqueous solution is described here. This compound represents an optimized alternative to dabcyl in a variety of biomolecular applications, like fluorogenic protease substrates or nucleic acids probes.

Abstract: A vanillin is found to be a useful starting material for preparing new monomers that can be further applied to make high Tg composite resins that are in turn useful for making composite parts.

Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.

Abstract: There is disclosed a process for producing taurine from ammonium isethionate by the ammonolysis of alkali isethionate in the presence of alkali ditaurinate or alkali tritaurinate, or their mixture, to inhibit the formation of byproducts and to continuously convert the byproducts of the ammonolysis reaction to alkali taurinate. Alkali taurinate is reacted with ammonium isethionate to obtain taurine and to regenerate alkali isethionate. The production yield is increased to from 90% to nearly quantitative. The ammonolysis reaction is catalyzed by alkali salts of hydroxide, sulfate, sulfite, phosphate, or carbonate.

Abstract: The present invention provides a method for producing a high-quality internal olefin sulfonate in which the content of any internal olefin and inorganic substance is small. This method for producing an internal olefin sulfonate, comprising: a sulfonating step of causing an internal olefin to react with sulfur trioxide to yield a sulfonated internal olefin; a neutralizing step of mixing the resultant sulfonated internal olefin with an aqueous alkaline solution at 40° C. or lower to yield a mixture, and applying shearing force to the mixture until the particle diameter of oil droplets of an oily product of the mixture turns to 10 ?m or less to yield a neutralized product; and a hydrolyzing step of hydrolyzing the resultant neutralized product.

Abstract: Quaternary ammonium, betaine, or sulfobetaine compositions derived from fatty amines, wherein the fatty amine is made by reducing the amide reaction product of a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives and a secondary amine, are disclosed. Quaternary ammonium, betaine, or sulfobetaine compositions derived from fatty amidoamines, wherein the amidoamine is made by reacting of a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives and an aminoalkyl-substituted tertiary amine, are also disclosed. The quaternized compositions are advantageously sulfonated or sulfitated. In one aspect, the ester derivative of the C10-C17 monounsaturated acid or octadecene-1,18-dioic acid is a lower alkyl ester. In other aspects, the ester derivative is a modified triglyceride N made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin.

Abstract: The present invention relates to processes for preparing for preparing 3-(methylsulfonyl)propionitrile. The processes comprise the steps of first reacting 2-chloroethyl methyl sulfide with sodium cyanide or potassium cyanide in a solvent or a solvent mixture to form 3-(methylthio)propionitrile, and then reacting the isolated 3-(methylthio)propionitrile with acetic anhydride, acetic acid, and hydrogen peroxide to form 3-(methylsulfonyl)propionitrile.

Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

Abstract: The present invention relates to compounds of general formula (I): wherein Y, R1, R2 and R3 are as defined in the specification. The invention also relates to cosmetic or dermocosmetic composition containing such compounds. The compounds according to the invention are useful as photoprotective agents.

Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

Abstract: A method for the purification of cyclic indole compounds that provides advantages over previously-known methods. Using the method of the present invention allows for the facile preparation of a good quality solid form of these compounds.

Abstract: A compound represented by formula (7): or a salt thereof can be manufactured by the following steps: a step of allowing a compound represented by formula (1-S): to react with a compound represented by formula (2): R2SM2??(2) to give a compound represented by formula (3-S): a step of allowing the compound represented by formula (3-S) to react with hydrogen peroxide in the presence of a tungsten catalyst and an acid to give a compound represented by formula (6-S) or a salt thereof: and a step of reducing the compound represented by formula (6-S) or salt thereof in the presence of a base and a heterogeneous transition metal catalyst to give a compound represented by formula (7) or a salt thereof, wherein X, R1, R2, and M2 are defined in the specification.

Abstract: The present invention aims to provide a novel low-molecular-weight compound having an orexin agonist activity, which is expected to be useful as a superior agent for the treatment or prophylaxis of narcolepsy. The present invention provides a compound showing superior orexin agonist activity which is represented by the formula (I) wherein each symbol is as defined in the DESCRIPTION, and a pharmaceutically acceptable acid addition salt thereof, as well as an orexin agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

Abstract: (E)-2-(2-Quinolin-2-yl-propenyl)-phenol, 2-Quinolin-2-yl-ylethynyl-phenol and salts thereof are useful as medicaments, especially for treatment of an angiogenesis-related disease or disorder.

Abstract: The present disclosure provides novel crystalline forms of cabozantinib (S)-malate, designated as form-M1, M2, M3 and M4 and novel crystalline forms of cabozantinib free base, form-M1, M2 and M3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (S)-malate form N-1.

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.

Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

Abstract: The present application relates to novel heterocyclic compounds, to the use thereof for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for preparation of the heterocyclic compounds.

Abstract: Articles and methods comprising persistent carbenes are provided, as well as related compositions. In some embodiments, a persistent carbene may be associated with a portion of a substrate (e.g., at least a portion of a surface on the substrate). In certain embodiments, the association of persistent carbene with the substrate may be used to affect certain properties of substrate (e.g., surface chemistry, stability). In some cases, a persistent carbene may be functionalized after association with a portion of a substrate. In some embodiments, a persistent carbene and at least one secondary compound may be associated with a portion of a substrate. Articles and methods of the present invention may be useful for applications involving electronics, sensing, microfabrication, nanotechnology, biomimetic, and drug delivery, amongst others.

Abstract: Disclosure is provided for imidazole derivative compounds useful to inhibit the formation of biofilms and/or inhibit microbial growth, compositions including these compounds, devices including these compounds, and methods of using the same.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.

Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: The present invention relates to compounds of the formula I and their use as fungicides, wherein the variables are defined as described in the claims and the specification.

Abstract: Provided are a surface-modifying agent that enables production of a coating film that preserves transparency of a substrate while displaying high water repellency and excellent stain resistance, particularly in terms of wipeability of oil-based ink, and also an article for which the surface-modifying agent is used. The surface-modifying agent includes a triazine skeleton, a (meth)acrylate group bonded to the triazine skeleton via an urethane bond, and a perfluoropolyether chain bonded to the triazine skeleton.

Abstract: Disclosed is a process for the integrated production of urea and melamine. A urea production zone produces a urea synthesis stream comprising urea, water and ammonium carbamate. This stream is subjected to processing, preferably involving stripping, so as to separate an aqueous urea stream from residual dissociated carbamate vapor comprising ammonia, carbon dioxide, and water. The urea is fed to a melamine synthesis zone and subjected to melamine forming conditions so as to form melamine and off-gas comprising carbon dioxide and ammonia. The dissociated carbamate vapor and the melamine off-gas are subjected to combined condensation so as to form a dilute melamine off-gas condensate.

Abstract: The present invention relates to a method of refining valsartan comprising more than or equal to 10% D-isomers, the method comprising: adding a solvent to valsartan comprising more than or equal to 10% D-isomers to dissolve it, then adding a certain amount of inorganic base, separating solids out after salification, distilling a filtrate after filtration, and distilling the filtrate to remove the organic solvent; adjusting the pH of the filtrate with an acid, extracting with an organic solvent, concentrating most of the organic solvent, cooling to crystallize, and obtaining the product. The method enables isomers of the product to be below 0.5%, and produce a yield of more than or equal to 40%, being suitable for industrial production.

Abstract: N-(1-Methyltetrazol-5-yl)benzamides of the general formula (I) are described as herbicides. In this formula (I), X, Z and R are radicals such as alkyl and cycloalkyl.

Abstract: The present invention relates to processes for the preparation of substituted cycloserine compounds of formula (I) wherein R1 is C1-C8alkyl, C1-C8haloalkyl, C3-C6 cycloalkyl, aryl or aryl substituted by one to five R11, or aryl-C1-C4alkylene or aryl-C1-C4alkylene substituted by one to five R11; and each R11 is independently C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, cyano or halogen; The invention also relates to intermediates produced by the processes. Compounds of formula (I) are useful intermediates for the production of compounds in the agricultural and pharmaceutical fields.

Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present invention provides an improved process for the preparation of 4?-acetoxy-2?-benzoyloxy-5?,20-epoxy-1?,13?-dihydroxy-7?,10?-dimethoxy-9-oxo-11-taxene (7?,10?-dimethoxy-10-deacetoxybaccatin III). The present invention also provides a novel process for the preparation of cabazitaxel.

Abstract: An object of the present invention is to provide a method for suppressing the corrosion of a reactor and reducing waste in the production of 2-furaldehyde from a sugar raw material containing a hexose as a constituent component, and another object of the invention is to provide an industrially advantageous method for producing 2-furaldehyde, which suppresses a decrease in the activity of a catalyst in a case of using an acid catalyst and provides a higher yield. The present invention relates to a method for producing 2-furaldehyde comprising heating a sugar raw material containing a hexose as a constituent component in an aprotic polar solvent in the presence of a solid acid catalyst.

Abstract: Methods for recovering monomers from polymers, such as polyurethanes (including thermoset polyurethanes) include heating the polymer to depolymerize the polymer and release the monomer. The monomer may be directly recovered. The polymer may include a poly(?-methyl-?-valerolactone) (PMVL) block and the monomer recovered may be ?-methyl-?-valerolactone (MVL).

Abstract: The present invention relates to a synthesis of chromanones or chromanes in a stereospecific matter in view of the 2-position in the chromanone or chromane ring. It has been found that this synthesis is particularly possible in the presence of a chiral compound of formula of a specific type and of at least one phenol or thiophenol.

Abstract: A method of cannabinoid preservation includes separating a cannabinoid ethanol (EtOH) mixture from a cannabis extract through a filtration process; forming a slurry by combining a crystalline compound with the cannabinoid EtOH mixture; heating and agitating the slurry in a pressurized chamber to form a colloidal cannabinoid EtOH mixture; distributing the colloidal cannabinoid EtOH mixture into a tray to form an evenly distributed mixture layer; forming an evaporation vessel for the evenly distributed mixture layer through the attachment of a detachable cover to the tray; positioning and heating the evaporation vessel within a heating chamber; performing a rapid cools process as the evenly distributed mixture layer approaches approaches saturation temperature; repeating the rapid cooling process until crystal formation is detected within the evenly distributed mixture layer; and/or removing the evaporation vessel from the heating chamber upon detection of crystal formation.